These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15120037

  • 1. The hollow fibre model in cancer drug screening: the NCI experience.
    Decker S, Hollingshead M, Bonomi CA, Carter JP, Sausville EA.
    Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037
    [Abstract] [Full Text] [Related]

  • 2. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR.
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
    Peterson JK, Houghton PJ.
    Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.
    Suggitt M, Swaine DJ, Pettit GR, Bibby MC.
    Clin Cancer Res; 2004 Oct 01; 10(19):6677-85. PubMed ID: 15475458
    [Abstract] [Full Text] [Related]

  • 6. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
    Suggitt M, Bibby MC.
    Clin Cancer Res; 2005 Feb 01; 11(3):971-81. PubMed ID: 15709162
    [Abstract] [Full Text] [Related]

  • 7. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs.
    Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, Double JA.
    Cancer Res; 1998 Dec 01; 58(23):5263-6. PubMed ID: 9850044
    [Abstract] [Full Text] [Related]

  • 8. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
    Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC.
    Anticancer Res; 2005 Dec 01; 25(3B):1889-94. PubMed ID: 16158922
    [Abstract] [Full Text] [Related]

  • 9. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu FF.
    Clin Cancer Res; 2006 Sep 15; 12(18):5557-69. PubMed ID: 17000693
    [Abstract] [Full Text] [Related]

  • 10. In vitro assays of chemotherapeutic sensitivity.
    Carney DN, Winkler CF.
    Important Adv Oncol; 1985 Sep 15; ():78-103. PubMed ID: 3916747
    [Abstract] [Full Text] [Related]

  • 11. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
    Wallqvist A, Huang R, Covell DG.
    J Chem Inf Model; 2007 Sep 15; 47(4):1414-27. PubMed ID: 17555311
    [Abstract] [Full Text] [Related]

  • 12. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
    Voskoglou-Nomikos T, Pater JL, Seymour L.
    Clin Cancer Res; 2003 Sep 15; 9(11):4227-39. PubMed ID: 14519650
    [Abstract] [Full Text] [Related]

  • 13. New anticancer agents: in vitro and in vivo evaluation.
    Zips D, Thames HD, Baumann M.
    In Vivo; 2005 Sep 15; 19(1):1-7. PubMed ID: 15796152
    [Abstract] [Full Text] [Related]

  • 14. Human tumor testsystems: a new screening approach.
    Kraemer HP, Sedlacek HH.
    Behring Inst Mitt; 1986 Jun 15; (80):103-12. PubMed ID: 3753367
    [Abstract] [Full Text] [Related]

  • 15. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
    Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, Sausville EA.
    Br J Cancer; 2001 May 18; 84(10):1424-31. PubMed ID: 11355958
    [Abstract] [Full Text] [Related]

  • 16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 18; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 17. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 18; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

  • 18. The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
    Suggitt M, Cooper PA, Shnyder SD, Bibby MC.
    Int J Oncol; 2006 Dec 18; 29(6):1493-9. PubMed ID: 17088988
    [Abstract] [Full Text] [Related]

  • 19. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A, Iakovou K, Gikas E, Fichtner I, Fiebig HH, Kelland LR, Double JA, Bibby MC, Hendriks HR.
    Anticancer Res; 2004 Dec 18; 24(2B):907-19. PubMed ID: 15161044
    [Abstract] [Full Text] [Related]

  • 20. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA, Spanswick VJ, Brooks N, Clingen PH, McHugh PJ, Hochhauser D, Pedley RB, Kelland LR, Alley MC, Schultz R, Hollingshead MG, Schweikart KM, Tomaszewski JE, Sausville EA, Gregson SJ, Howard PW, Thurston DE.
    Cancer Res; 2004 Sep 15; 64(18):6693-9. PubMed ID: 15374986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.